Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | TRPV4 | Q9HBA0 | 9/20 | 0.46 |
| ▸ | ITGA1 | P56199 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360908 | 1.00 | GBA1 (0.55) | GBA1TRPV4ITGA1RAB9AMEN1 | |
| SCHEMBL5447807 | 0.86 | GBA1 (0.59) | GBA1TRPV4CCR1ATM | |
| SCHEMBL5447814 | 0.86 | GBA1 (0.59) | GBA1TRPV4CCR1ATM | |
| SCHEMBL5440181 | 0.82 | ITGA1 (0.47) | TRPV4ITGA1RAB9AMEN1LMNA | |
| SCHEMBL6755655 | 0.79 | ATM (0.58) | TRPV4ITGA1RAB9AMEN1LMNA | |
| SCHEMBL14360833 | 0.76 | IDO1 (0.44) | TRPV4ITGA1RAB9AMEN1MAPT | |
| SCHEMBL3915576 | 0.76 | RAB9A (0.42) | TRPV4ITGA1RAB9AMEN1KMT2A | |
| SCHEMBL3915580 | 0.76 | RAB9A (0.42) | TRPV4ITGA1RAB9AMEN1ALOX12 | |
| SCHEMBL4777734 | 0.74 | TRPV4 (0.55) | TRPV4CCR1 | |
| SCHEMBL4128136 | 0.74 | CYP3A4 (0.58) | TRPV4MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | GBA1 1769/4885TRPV4 1/4885ITGA1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.